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Background: Cardiovascular disease (CVD) is reported to be higher in elderly diabetics. Serum 
heart-type fatty acid binding protein (H-FABP) is a serum marker of myocardial ischemia. We 
aimed to investigate the association between serum H-FABP level and conventional cardio-
vascular risk factors, inflammatory markers and subclinical atherosclerosis in elderly diabetics 
without overt CVD.
Patients and methods: A total of 50 elderly diabetic patients without overt CVD and 
30 age-, sex- and body mass index (BMI)-matched healthy controls were enrolled. Anthro-
pometric and biochemical parameters, serum H-FABP, high-sensitivity C-reactive protein 
(hs-CRP), fibrinogen and carotid intima-media thickness (CIMT) were measured. Logistic regres-
sion analyses (adjustments for age, sex, hypertension, smoking, diabetes, BMI, blood pressure, 
lipid, blood glucose, hemoglobin A1c, hs-CRP and fibrinogen) were performed to evaluate the 
association between H-FABP and cardiovascular risk factors and atherosclerosis indices.
Results: Serum fibrinogen (421.50±85.52 mg/dL vs 319.17±30.77 mg/dL, p=0.023), CIMT 
(0.70±0.12 mm vs 0.59±0.06 mm, p,0.001) and hs-CRP (5.72±4.50 mg/dL vs 1.60±0.72 mg/dL, 
p,0.001) were significantly higher in diabetic patients than controls. The mean serum H-FABP 
level did not differ between groups (1571.79±604.60 ng/mL vs 1500.25±463.35 ng/mL, 
p=0.905). H-FABP was positively correlated with fibrinogen (r2=0.473, p,0.001), hs-CRP 
(r2=0.323, p=0.003) and CIMT (r2=0.467, p,0.001). After full adjustments, the serum 
H-FABP level was independently associated with an increase in the fibrinogen level (odds ratio 
[OR] =4.21, 95% confidence level [CI] =1.49–11.90).
Conclusion: Serum H-FABP was similar in the elderly diabetic patients without known CVD 
when compared with the nondiabetic control group. H-FABP does not possess a high diag-
nostic value as a cardiovascular marker when used alone; however, it may add supplementary 
information in patients with a high fibrinogen level.
Keywords: H-FABP, elderly diabetics, cardiovascular risk
Introduction
Considering the aging population and increased obesity, diabetes is increasingly 
becoming a serious public health issue especially among the elderly.1,2 It has been esti-
mated that one-third of the elderly are diabetic, whereas three-quarters are prediabetic.3 
Prevalence of cardiovascular disease (CVD),4 myocardial infarction (MI)5 and CVD-
related mortality6 has been reported to be higher in diabetic patients older than 65 years 
when compared to their nondiabetic peers. Coronary artery disease (CAD) is the lead-
ing cause of mortality with the highest prevalence in this group of patients.6,7 Silent 
ischemia is another health issue among elderly diabetic patients.7,8 Of all elderly cases 
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of MI, 12%–33% of males and 26%–54% of females are 
symptomatic or might not get an accurate diagnosis.9 Inflam-
mation plays a major role in atherosclerosis.4,10,11 Inflam-
matory markers such as high-sensitivity C-reactive protein 
(hs-CRP) and fibrinogen are useful in the determination of 
CVD risk.4,10–12 Subclinical atherosclerosis is characterized 
by increased carotid intima-media thickness (CIMT) and has 
been reported to independently predict future cardiovascular 
events (MI/ischemia and angina).13
Heart-type fatty acid binding protein (H-FABP) is a small 
cytoplasmic protein with a low molecular weight of 15 kDa. 
It is mainly found in the heart but is also present, to a lesser 
extent, in circulation and extracardiac tissues.14 Physiologic 
function of H-FABP is the transport of hydrophobic long-
chain fatty acids from cell membrane to intracellular spaces 
of mitochondrial metabolism, by means of which they join the 
citric acid cycle.10 In the case of acute myocardial infarction 
(AMI), H-FABP is released in large quantities from myo-
cytes into circulation at an early stage.14 It possesses a high 
diagnostic sensitivity and specificity in AMI and myocardial 
ischemia and hence could be used as a serum marker of acute 
coronary syndrome (ACS) and myocardial injury.14,15 Several 
studies were conducted especially among patients without 
overt CVD but with a high mortality and morbidity risk for 
cardiovascular events associated with atherosclerosis and 
inflammatory state. It is demonstrated that H-FABP could be 
utilized in the determination of subclinical myocardial injury 
or subclinical atherosclerosis. To date, the role of H-FABP 
in a number of diseases that pose a risk for cardiovascular 
events such as metabolic syndrome (MS),17 nonalcoholic fatty 
liver disease (NAFLD),18 impaired glucose metabolism,19 
acromegaly,20 hypothyroidism21 and insulin-resistant poly-
cystic ovary syndrome (PCOS)22 has been investigated by 
several studies. It is known that diabetic patients have silent 
subclinical myocardial injury associated with hyperglycemia, 
atherosclerosis and inflammation.7,8,23,24 To the best of our 
knowledge, there is no study in the literature investigating 
H-FABP as a marker of subclinical myocardial injury in a 
population that is at a high risk for CVD, namely, elderly 
diabetics. In this respect, this is the first study that investigates 
the association between H-FABP as a marker of subclinical 
myocardial injury and inflammatory and subclinical athero-
sclerosis markers16 in patients at a high risk for CVD. The 
purpose of this study is to investigate the association between 
the serum H-FABP level and conventional cardiovascular 
risk factors (blood pressure, blood glucose, lipid, smoking 
and body mass index [BMI]), inflammatory markers (hs-CRP 
and fibrinogen) and subclinical atherosclerosis (CIMT) in 
elderly diabetics without overt CVD.
Patients and methods
A total of 50 elderly (age $65 years) diabetic patients 
without overt CVD and 30 sex- and BMI-matched elderly 
(age $65 years) controls were enrolled in the study. The 
exclusion criteria included age ,65 years, poorly controlled 
diabetes (hemoglobin A1c [HbA1c] $11%), the presence 
of overt CVD (significant valvular heart disease, dilated 
cardiomyopathy, heart failure, history of ACS), serum 
creatinine $2.5 mg/dL, stroke, severe systemic disease, 
bedridden status and history of muscle disease. Sex and BMI-
matched elderly controls were selected without diabetes, 
CVD or any chronic disease. Each subject signed an informed 
consent form in accordance with the Declaration of Helsinki, 
and this study was approved by the local ethical committee 
of Dişkapi Training and Research Hospital (114/2015).
Baseline demographic data, clinical characteristics, blood 
sampling and CIMT were obtained in all study subjects. 
Blood pressure, weight, height and BMI were also mea-
sured. Hypertension was defined as resting systolic blood 
pressure (SBP) .140 mmHg or diastolic blood pressure 
(DBP) .90 mmHg at two different visits or using antihyper-
tensive medication. Dyslipidemia was defined as low-density 
lipoprotein cholesterol (LDL-C) .100 mg/dL, high-density 
lipoprotein cholesterol (HDL-C) ,40 mg/dL in men 
and ,50 mg/dL in women and triglycerides (TGs) .150 mg/dL 
and/or the prescription of anti-lipidemic medications.
Fasting plasma glucose (FPG) and postprandial plasma 
glucose (PPG), serum total cholesterol, TG, HDL-C, LDL-C 
and hs-CRP measurements were performed by Beckman 
Coulter AU5800 (Beckman Coulter Inc., Brea, CA, USA) 
autoanalyzer. Fibrinogen was measured by ADVIA Cen-
taur XP (Siemens Healthcare Diagnostics Inc., Tarrytown, 
NY, USA). HbA1c was measured by ion-exchange high- 
performance liquid chromatography (Tosoh Corporation, 
Tokyo, Japan). Serum H-FABP was measured by an enzyme-
linked immunosorbent assay (Hycult Biotech, Uden, the Neth-
erlands). Renal function was evaluated by the estimated 
glomerular filtration rate (eGFR). eGFR was calculated with 
the Modification of Diet in Renal Disease equation: e GFR 
(mL/min/1.73 m2) = 186 × serum creatinine (mg/dL)−1.154 × age 
(years)−0.203 × 0.742 (if female). CIMT was measured for assess-
ing carotid atherosclerosis. CIMT was defined as the distance 
between the blood–intima and media–adventitia boundaries 
on the B-mode imaging high-resolution ultrasound system 
(Sonoline G4; Siemens, North Middletown, NJ, USA).
statistical analyses
Statistical analysis was performed using SPSS 18.0 (SPSS 
Inc., Chicago, IL, USA) software. Variables are presented as 
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mean ± standard deviation (SD) or median (with interquartile 
range) values, percentages (%), odds ratios (ORs) and 95% 
confidence intervals (CIs). Normality was tested using the 
Kolmogorov–Smirnov and Shapiro–Wilk W test. Categorical 
variables were analyzed using the chi-square test or Fisher’s 
exact test, where appropriate. The Student’s t-test was used 
for normally distributed continuous variables. The Mann–
Whitney U-test was used for continuous variables that were 
not normally distributed. Correlations were analyzed using 
Pearson and Spearman correlation methods. In multiple 
logistic regression analyses, adjustments for age, sex, hyper-
tension, smoking, diabetes, BMI, SBP, DBP, eGFR, TG, total 
cholesterol, HDL-C, LDL-C, FPG, PPG, HbA1c, hs-CRP and 
fibrinogen were carried out. The adjusted variables associ-
ated with H-FABP (log transformed) requiring a probability 
value of ,0.200 were entered. Statistical significance was 
defined as p,0.05.
Results
Clinical and metabolic parameters of subjects are shown 
in Table 1. We studied 50 elderly diabetic patients (age 
70.52±5.81 years, 46.0% males, BMI 29.09±4.77 kg/m2) and 
30 age-, sex- and BMI-matched elderly nondiabetic patients 
(age 70.23±5.94 years, 43.3% males, BMI 29.30±5.50 kg/m2). 
The duration of diabetes was 12.84±8.05 years. In all, 88.0% 
of diabetic patients were maintained on oral antidiabetic drugs 
and insulin therapy and 52.0% of diabetic patients were main-
tained on only insulin therapy. Blood pressure, FPG, PPG and 
HbA1c levels were higher in elderly diabetic patients than 
in elderly nondiabetic patients (p,0.05). Hypertension and 
dyslipidemia were higher in elderly diabetic patients than in 
elderly nondiabetic patients (p,0.001). Since 31 (62.0%) 
diabetic patients were maintained on the antilipidemic agent, 
mean TG, LDL-C and HDL-C levels were similar between 
groups. Overweight/obesity and smoking habits were similar 
between groups (p.0.05). Fibrinogen (421.50±85.52 mg/dL 
vs 319.17±30.77 mg/dL, p=0.023), CIMT (0.70±0.12 mm vs 
0.59±0.06 mm, p,0.001) and hs-CRP (5.72±4.50 mg/dL 
vs 1.60±0.72 mg/dL, p,0.001) were higher in elderly 
diabetic patients than in non-elderly diabetic patients. The 
H-FABP level was not significantly different between 
elderly diabetic patients and elderly nondiabetic patients 
(1,571.79±604.60 ng/mL vs 1,500.25±463.35 ng/mL, 
p=0.905). H-FABP was not different between elderly non-
diabetic patients and elderly diabetic patients after adjusted 
for sex. H-FABP was positively correlated with fibrinogen 
(r2=0.473, p,0.001), hs-CRP (r2=0.323, p=0.003) and 
CIMT (r2=0.467, p,0.001) and negatively correlated with 
eGFR (r2=−0.635, p,0.001; Table 2). After full adjustments, 
elevated log-transformed H-FABP was associated with 
an increased fibrinogen (OR =4.21, 95% CI =1.49–11.90, 
p=0.04). The diabetic patients were divided into two groups 
according to the upper normal level of fibrinogen. H-FABP 
levels were higher in diabetic patients with the fibrinogen 
level .390 mg/dL than in the diabetic patients with the fibrin-
ogen level ,390 mg/dL (1,886.39–1,305.23, p,0.001).
Discussion
In this study, H-FABP was independently associated with 
fibrinogen in elderly diabetic patients who were at a high 
Table 1 Characteristics of elderly diabetics and elderly non-
diabetics
Variables Elderly 
diabetics 
(n=50)
Elderly 
nondiabetics 
(n=30)
p-value
Male, n (%) 23 (46.0) 13 (43.3) 0.816
Overweight/obesity, n (%) 20 (40.0) 14 (46.7) 0.559
hypertension, n (%) 42 (84.0) 0 ,0.001
Dyslipidemia, n (%) 37 (74.0) 0 ,0.001
smoking habits, n (%) 8 (16.0) 3 (10.0) 0.451
Age (years)a 70.52±5.81 70.23±5.94 0.547
BMI (kg/m2)a 29.49±4.77 29.30±5.50 0.960
Office SBP (mmHg)a 139.40±17.69 121.33±7.65 ,0.001
Office DBP (mmHg)a 89.40±14.63 74.50±6.21 ,0.001
FPg (mg/dl)a 149.36±40.74 80.63±9.96 ,0.001
PPg (mg/dl)a 243.70±58.34 108.77±17.30 ,0.001
hbA1c (%)a 8.35±1.77 5.79±0.35 ,0.001
Total cholesterol (mg/dl)a 188.42±35.81 177.03±20.61 0.075
Tg (mg/dl)a 147.46±62.62 140.67±56.26 0.728
hDl-C (mg/dl)a 46.32±12.93 48.97±10.30 0.129
lDl-C (mg/dl)a 120.72±32.53 112.30±18.92 0.147
egFr (ml/min/1.73 m2)a 87.59±23.00 94.46±22.59 0.197
hs-CrP (mg/dl)a 5.72±4.50 1.60±0.72 ,0.001
CIMT score (mm)a 0.70±0.12 0.59±0.06 ,0.001
h-FABP (ng/ml)a 1,571.79±604.60 1,500.25±463.35 0.905
Fibrinogen (mg/dl)a 421.50±85.52 319.17±30.77 0.023
Notes: Data are shown as median or percentage. aData are shown as mean ± sD.
Abbreviations: BMI, body mass index; CIMT, carotid intima-media thickness; 
DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, 
fasting plasma glucose; hbA1c, hemoglobin A1c; hDl-C, high-density lipoprotein 
cholesterol; h-FABP, heart-type fatty acid binding protein; hs-CrP, high sensitivity 
C-reactive protein; lDl-C, low-density lipoprotein cholesterol; PPg, postprandial 
plasma glucose; sBP, systolic blood pressure; Tg, triglyceride.
Table 2 Correlation of h-FABP with cardiovascular risk 
parameters
Variables r2 p-value
CIMT 0.467 ,0.001
Fibrinogen 0.473 ,0.001
hs-CrP 0.323 0.003
egFr −0.635 ,0.001
Abbreviations: CIMT, carotid intima-media thickness; egFr, estimated glomerular 
filtration rate; H-FABP, heart-type fatty acid binding protein; hs-CRP, high sensitivity 
C-reactive protein.
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risk for cardiovascular events. Serum H-FABP, a marker 
of myocardial ischemia, does not possess a high diagnostic 
value when used alone in the determination of cardiovas-
cular risk.
In an experimental diabetic model, it was reported that 
the fatty acid-binding protein content of rat heart was sig-
nificantly high. It could cause faster consumption of fatty 
acid in the diabetic heart.15 As H-FABP is a small soluble 
protein, it is released much more rapidly into circulation in 
response to cardiomyocyte damage than structural proteins 
such as cardiac troponin.25–27 Therefore, it can be used as a 
sensitive diagnostic marker in the early stage of AMI.25,26,28 
It can be used to predict long-term mortality in ACS26 and 
future cardiovascular events in dilated cardiomyopathy.29 
In addition, it was reported that it could be helpful in the 
early determination of postoperative myocardial mortality 
in patients undergoing coronary bypass surgery.30 Sari et al31 
detected increased perioperative cardiovascular risk by means 
of early postoperative H-FABP measurements after elective 
noncardiac surgery in diabetic patients. Several studies found 
patients without overt CVD but with the cardiovascular 
risk associated with atherosclerosis and inflammatory state. 
These studies showed that serum H-FABP measurements 
might be used for determination of subclinical myocardial 
injury or subclinical atherosclerosis. It was demonstrated 
that H-FABP could be helpful in the determination of low-
level myocardial injury in hypothyroidism21 and early stage 
atherosclerosis in PCOS22 and prediabetes.32 Patients with 
the NAFLD were shown to have both subclinical myocardial 
injury and subclinical atherosclerosis by H-FABP measure-
ments, independent of MS and cardiovascular risk factors.18 
H-FABP measurements could be determined through myo-
cardial injury in the asymptomatic period in diabetic and even 
nondiabetic patients with MS.17 Thus, elevated H-FABP level 
suggests having a myocardial injury and/or a high risk for 
cardiovascular events.31,33 In the present study, the H-FABP 
level did not differ between elderly diabetic patients and 
elderly nondiabetic patients. Subclinical atherosclerosis 
(CIMT) and inflammatory markers (fibrinogen and hs-CRP) 
were higher in elderly diabetic patients. H-FABP positively 
correlated with fibrinogen, hs-CRP and CIMT in univariate 
analysis. After full adjustment, H-FABP was independently 
associated with fibrinogen in elderly diabetic patients who 
were at a high risk for cardiovascular events (OR =4.21, 95% 
CI =1.49–11.90, p=0.04).
Age- and sex-adjusted H-FABP was associated with male 
sex; however, this association disappeared after adjustment 
for additional cardiovascular risk factors. In addition, the 
frequency of smoking was higher in patients with high 
H-FABP levels; however, no association was found between 
H-FABP and smoking after full adjustment. In agreement 
with the previous studies,18,21,22,25–31,34 the present study dem-
onstrated an association between H-FABP and conventional 
cardiovascular risk factors, atherosclerosis and inflammatory 
markers. This partially suggests that H-FABP can be used 
as a marker of cardiovascular risk, especially in elderly 
diabetic patients. Both CRP and fibrinogen are acute-phase 
reactants secreted from hepatocytes after cytokine release 
has been triggered in the immune system.4,10,11,35 Fibrinogen 
plays a particular role in coagulation. Epidemiological stud-
ies showed that elevation in fibrinogen was an independent 
risk factor for future cardiovascular events.10,11 Serum CRP 
is used as a surrogate marker of CVD.4 It was reported that 
a combination of CRP and fibrinogen was associated with 
all-cause mortality and CVD-related mortality.36 Diabetes 
and related diseases in urban indigenous population in the 
Darwin Region study demonstrated that fibrinogen levels 
increased with age in a population that was at a high risk 
for CVD and were higher in diabetic patients compared to 
nondiabetic patients.11 In addition, the Strong Heart Study 
reported that not CRP but fibrinogen was a useful marker in 
the determination of CVD risk.12 The present study showed 
an association between H-FABP and inflammatory markers 
(fibrinogen and hs-CRP). This association between H-FABP 
and fibrinogen did not disappear after full adjustment. As 
fibrinogen increases with age and diabetes,11,12 the combina-
tion of fibrinogen and H-FABP might be useful in assessing 
CVD risk, especially in elderly diabetic patients.
Studies reported an association between CIMT and 
CRP and/or fibrinogen in elderly patients with subclini-
cal atherosclerosis;37,38 this association could not be veri-
fied after adjustment for conventional risk factors including 
adiposity.35–39 Studies reported a positive correlation between 
inflammatory markers and CIMT in elderly;37,38,40 however, 
these studies were performed without adjustment for conven-
tional cardiovascular risk factors, including obesity.
There is no evidence about an association between inflam-
matory markers and CIMT after adjustment for conven-
tional cardiovascular risk factors including obesity in elderly. 
The present study demonstrated an association between inflam-
matory markers and subclinical atherosclerosis. Although the 
immune system is involved in every stage of atherosclerotic 
disease, CRP and fibrinogen remain low in the early stage and 
tend to increase as atherosclerosis progresses.35 Therefore, 
fibrinogen and CRP indicate the extent of the atheroscle-
rotic burden and help predict cardiovascular events.4,10,11,35,36 
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This study showed that H-FABP was associated with other 
factors (hs-CRP and CIMT). It was suggested that these 
proteins are involved less in early plaque development than 
fibrinogen. CIMT measurement is a precursor to very serious 
symptomatic disease;37,38,40 thus, it was not useful for assessing 
atherosclerosis in early atherosclerosis. Such factors as muscle 
wasting and renal insufficiency25 should not be overlooked 
when interpreting H-FABP values, especially in the elderly.
CVD-related mortality and morbidity and the causal 
relationship could not be determined in this cross-sectional 
study. The H-FABP level was not different in elderly dia-
betic patients and elderly nondiabetic patients; this result 
might have been caused by the limited number of subjects 
included in the study. In this respect, larger prospective 
studies are needed that will investigate the potential associa-
tion between H-FABP and conventional cardiovascular risk 
factors, inflammatory markers and atherosclerosis. These are 
limitations of this study.
Limitations of H-FABP that prevent its widespread 
utilization as a diagnostic marker include the following: it 
is present in both cardiac and skeletal muscles, thus has a 
limited cardiospecificity; it has a narrow diagnostic window 
and it might end in false high values in the case of renal 
insufficiency.14,16,25–27 In the present study, H-FABP, a marker 
of myocardial ischemia, did not differ between elderly dia-
betic patients and elderly nondiabetic patients. Nevertheless, 
univariate analysis showed that H-FABP was associated 
with the marker of inflammatory (hs-CRP and fibrinogen) 
and subclinical atherosclerosis (CIMT) in elderly diabetic 
patients. Multivariate analysis showed that H-FABP was 
independently associated with fibrinogen in elderly diabetic 
patients, and H-FABP levels were higher in patients with 
higher fibrinogen levels. Thus, H-FABP does not possess a 
high diagnostic value as a cardiovascular marker when used 
alone; however, it may add supplementary information in 
patients with a high fibrinogen level.
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